BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 28608996)

  • 1. Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group.
    Provencio M; Royuela A; Torrente M; Pollán M; Gómez-Codina J; Sabín P; Llanos M; Gumá J; Quero C; Blasco A; Aguiar D; García-Arroyo FR; Lavernia J; Martínez N; Morales M; Saenz-Cusi Á; Rodríguez D; Calvo V; de la Cruz-Merino L; de la Cruz MÁ; Rueda A;
    Cancer; 2017 Oct; 123(19):3709-3716. PubMed ID: 28608996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.
    Maurer MJ; Bachy E; Ghesquières H; Ansell SM; Nowakowski GS; Thompson CA; Inwards DJ; Allmer C; Chassagne-Clément C; Nicolas-Virelizier E; Sebban C; Lebras L; Sarkozy C; Macon WR; Feldman AL; Syrbu SI; Traverse-Glehan A; Coiffier B; Slager SL; Weiner GJ; Witzig TE; Habermann TM; Salles G; Cerhan JR; Link BK
    Am J Hematol; 2016 Nov; 91(11):1096-1101. PubMed ID: 27465588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry.
    Provencio M; Sabín P; Gomez-Codina J; Torrente M; Calvo V; Llanos M; Gumá J; Quero C; Blasco A; Cruz MA; Aguiar D; García-Arroyo F; Lavernia J; Martinez N; Morales M; Saez-Cusi A; Rodriguez D; de la Cruz L; Sanchez JJ; Rueda A;
    PLoS One; 2017; 12(5):e0177204. PubMed ID: 28493986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group.
    Méndez M; Torrente M; Sánchez-Beato M; González-Rincón J; Royuela A; Gómez-Codina J; de la Cruz-Merino L; Rueda A; Llanos M; Quero C; Rodríguez-Abreu D; Gumá J; Monsalvo S; Sabin P; Provencio M
    Hematol Oncol; 2019 Apr; 37(2):143-150. PubMed ID: 30840776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years.
    Barzenje DA; Cvancarova Småstuen M; Liestøl K; Fosså A; Delabie J; Kolstad A; Holte H
    PLoS One; 2015; 10(7):e0131158. PubMed ID: 26147646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
    Alonso-Álvarez S; Magnano L; Alcoceba M; Andrade-Campos M; Espinosa-Lara N; Rodríguez G; Mercadal S; Carro I; Sancho JM; Moreno M; Salar A; García-Pallarols F; Arranz R; Cannata J; Terol MJ; Teruel AI; Rodríguez A; Jiménez-Ubieto A; González de Villambrosia S; Bello JL; López L; Monsalvo S; Novelli S; de Cabo E; Infante MS; Pardal E; García-Álvarez M; Delgado J; González M; Martín A; López-Guillermo A; Caballero MD
    Br J Haematol; 2017 Sep; 178(5):699-708. PubMed ID: 28782811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.
    Maurer MJ; Ghesquières H; Jais JP; Witzig TE; Haioun C; Thompson CA; Delarue R; Micallef IN; Peyrade F; Macon WR; Jo Molina T; Ketterer N; Syrbu SI; Fitoussi O; Kurtin PJ; Allmer C; Nicolas-Virelizier E; Slager SL; Habermann TM; Link BK; Salles G; Tilly H; Cerhan JR
    J Clin Oncol; 2014 Apr; 32(10):1066-73. PubMed ID: 24550425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.
    Murakami S; Kato H; Higuchi Y; Yamamoto K; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
    Ann Hematol; 2016 Aug; 95(8):1259-69. PubMed ID: 27220639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study.
    Martinelli G; Montoro J; Vanazzi A; Andreola G; Liptrott S; Radice D; Negri M; Preda L; Pruneri G; Laszlo D
    Hematol Oncol; 2015 Dec; 33(4):129-35. PubMed ID: 25047267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.
    Sarkozy C; Maurer MJ; Link BK; Ghesquieres H; Nicolas E; Thompson CA; Traverse-Glehen A; Feldman AL; Allmer C; Slager SL; Ansell SM; Habermann TM; Bachy E; Cerhan JR; Salles G
    J Clin Oncol; 2019 Jan; 37(2):144-152. PubMed ID: 30481079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Treatment in Slovene Follicular Lymphoma Patients.
    Južnič Šetina T; Borštnar S; Jezeršek Novaković B
    Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):586-91. PubMed ID: 26423702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
    Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
    Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
    Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
    Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
    Taverna C; Martinelli G; Hitz F; Mingrone W; Pabst T; Cevreska L; Del Giglio A; Vanazzi A; Laszlo D; Raats J; Rauch D; Vorobiof DA; Lohri A; Biaggi Rudolf C; Rondeau S; Rusterholz C; Heijnen IA; Zucca E; Ghielmini M
    J Clin Oncol; 2016 Feb; 34(5):495-500. PubMed ID: 26712227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide real-world analysis from Taiwan Cancer Registry Database.
    Huang HH; Wen YC; Chen HM; Hsiao FY; Ko BS
    Cancer Med; 2018 Aug; 7(8):3582-3591. PubMed ID: 30009424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Patterns and Survival Outcomes in Patients With Follicular Lymphoma: A 2007 to 2015 Humedica Database Study.
    Morrison VA; Shou Y; Bell JA; Hamilton L; Ogbonnaya A; Raju A; Hennenfent K; Eaddy M; Galaznik A
    Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):e172-e183. PubMed ID: 30691994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte.
    Bachy E; Brice P; Delarue R; Brousse N; Haioun C; Le Gouill S; Delmer A; Bordessoule D; Tilly H; Corront B; Allard C; Foussard C; Bosly A; Coiffier B; Gisselbrecht C; Solal-Celigny P; Salles G
    J Clin Oncol; 2010 Feb; 28(5):822-9. PubMed ID: 20026809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients.
    Plancarte F; López-Guillermo A; Arenillas L; Montoto S; Giné E; Muntañola A; Ferrer A; Villamor N; Bosch F; Colomo L; Balaguer O; Campo E; Montserrat E
    Eur J Haematol; 2006 Jan; 76(1):58-63. PubMed ID: 16343272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cause-specific mortality in individuals with severe alpha 1-antitrypsin deficiency in comparison with the general population in Sweden.
    Tanash HA; Ekström M; Wagner P; Piitulainen E
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1663-9. PubMed ID: 27555756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.